JP4895505B2 - 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 - Google Patents

変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 Download PDF

Info

Publication number
JP4895505B2
JP4895505B2 JP2004506500A JP2004506500A JP4895505B2 JP 4895505 B2 JP4895505 B2 JP 4895505B2 JP 2004506500 A JP2004506500 A JP 2004506500A JP 2004506500 A JP2004506500 A JP 2004506500A JP 4895505 B2 JP4895505 B2 JP 4895505B2
Authority
JP
Japan
Prior art keywords
mva
igr
seq
sequence
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004506500A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005525822A (ja
Inventor
ハウレイ・ポール
ライラー・ゾンヤ
Original Assignee
バヴァリアン・ノルディック・アクティーゼルスカブ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バヴァリアン・ノルディック・アクティーゼルスカブ filed Critical バヴァリアン・ノルディック・アクティーゼルスカブ
Publication of JP2005525822A publication Critical patent/JP2005525822A/ja
Application granted granted Critical
Publication of JP4895505B2 publication Critical patent/JP4895505B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2004506500A 2002-05-16 2003-05-14 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 Expired - Lifetime JP4895505B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200200752 2002-05-16
DKPA200200753 2002-05-16
DKPA200200753 2002-05-16
DKPA200200752 2002-05-16
PCT/EP2003/005045 WO2003097845A1 (en) 2002-05-16 2003-05-14 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Publications (2)

Publication Number Publication Date
JP2005525822A JP2005525822A (ja) 2005-09-02
JP4895505B2 true JP4895505B2 (ja) 2012-03-14

Family

ID=29551228

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2004506500A Expired - Lifetime JP4895505B2 (ja) 2002-05-16 2003-05-14 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
JP2004506501A Expired - Lifetime JP4693092B2 (ja) 2002-05-16 2003-05-14 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2010176511A Pending JP2011004755A (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2010176512A Expired - Lifetime JP5777199B2 (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2004506501A Expired - Lifetime JP4693092B2 (ja) 2002-05-16 2003-05-14 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2010176511A Pending JP2011004755A (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス
JP2010176512A Expired - Lifetime JP5777199B2 (ja) 2002-05-16 2010-08-05 ポックスウイルスゲノムに挿入された相同遺伝子を発現させる組換えポックスウイルス

Country Status (22)

Country Link
US (14) US7550147B2 (cg-RX-API-DMAC7.html)
EP (3) EP1407033B1 (cg-RX-API-DMAC7.html)
JP (4) JP4895505B2 (cg-RX-API-DMAC7.html)
KR (4) KR101005630B1 (cg-RX-API-DMAC7.html)
CN (6) CN101831411A (cg-RX-API-DMAC7.html)
AT (1) ATE315660T1 (cg-RX-API-DMAC7.html)
AU (4) AU2003236646B2 (cg-RX-API-DMAC7.html)
BR (2) BR0310051A (cg-RX-API-DMAC7.html)
CA (3) CA2481521C (cg-RX-API-DMAC7.html)
DE (1) DE60303218T2 (cg-RX-API-DMAC7.html)
DK (2) DK1506301T3 (cg-RX-API-DMAC7.html)
EA (3) EA012160B1 (cg-RX-API-DMAC7.html)
ES (1) ES2256776T3 (cg-RX-API-DMAC7.html)
IL (4) IL164177A0 (cg-RX-API-DMAC7.html)
MX (2) MXPA04011194A (cg-RX-API-DMAC7.html)
NO (3) NO334273B1 (cg-RX-API-DMAC7.html)
NZ (2) NZ536501A (cg-RX-API-DMAC7.html)
PL (2) PL216760B1 (cg-RX-API-DMAC7.html)
PT (1) PT1407033E (cg-RX-API-DMAC7.html)
SI (1) SI1407033T1 (cg-RX-API-DMAC7.html)
UA (1) UA82479C2 (cg-RX-API-DMAC7.html)
WO (2) WO2003097845A1 (cg-RX-API-DMAC7.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4101327C1 (cg-RX-API-DMAC7.html) * 1991-01-18 1991-10-24 Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
NZ536592A (en) * 2002-04-19 2007-01-26 Bavarian Nordic As Modified vaccinia virus ankara for the vaccination of neonates
EP1407033B1 (en) 2002-05-16 2006-01-11 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
US7501127B2 (en) * 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
HK1080507B (zh) * 2002-09-05 2011-10-07 巴法里安诺迪克有限公司 在无血清条件下培养原代细胞和扩增病毒的方法
JP5052893B2 (ja) * 2003-02-20 2012-10-17 アメリカ合衆国 ポックスベクターにおける新規の挿入部位
GB2402391A (en) * 2003-06-04 2004-12-08 Oxxon Pharmaccines Ltd Fowlpox recombinant genome
EP1807508A4 (en) * 2004-11-05 2008-03-12 Us Gov Health & Human Serv METHODS FOR PREPARING CELLS AND VIRUSES
DK1855720T4 (da) 2005-02-23 2023-07-24 Bavarian Nordic As Anvendelse af et modificeret poxvirus til hurtig induktion af immunitet mod et poxvirus eller andre smitstoffer
CA2651456A1 (en) * 2006-05-19 2007-11-29 Glycofi, Inc. Recombinant vectors
US9133478B2 (en) 2006-08-25 2015-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified vaccinia Ankara (MVA) virus recombinants comprising heterologous coding sequences inserted into the intergenic regions between essential genes
US8052968B2 (en) * 2006-10-16 2011-11-08 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
US8440202B2 (en) * 2006-11-09 2013-05-14 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using the prime-boost approach
WO2008127307A2 (en) * 2006-11-09 2008-10-23 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
AU2008209759B2 (en) * 2007-01-30 2013-03-21 Transgene S.A. Papillomavirus E2 polypeptide used for vaccination
US8268327B2 (en) 2007-04-27 2012-09-18 Bavarian Nordic A/S Immediate protection against pathogens via MVA
US8337859B2 (en) * 2007-05-15 2012-12-25 Transgene S.A. Vectors for multiple gene expression
TW200907058A (en) * 2007-05-30 2009-02-16 Wyeth Corp Raccoon poxvirus expressing rabies glycoproteins
AU2008260593A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens
NZ584042A (en) * 2007-10-18 2012-09-28 Bn Immunotherapeutics Inc Use of mva to treat prostate cancer
US20110052627A1 (en) * 2008-06-20 2011-03-03 Paul Chaplin Recombinant modified vaccinia virus measles vaccine
KR100894430B1 (ko) * 2008-11-11 2009-04-22 시스템디엔디(주) 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법
EA024749B1 (ru) 2008-11-21 2016-10-31 Бавариан Нордик А/С Экспрессионный вектор со сниженным уровнем внутримолекулярной рекомбинации, содержащий гомологичные или гетерологичные нуклеотидные последовательности
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
CA2777744C (en) 2009-10-16 2019-09-24 Bernard Moss Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites
US20110159031A1 (en) * 2009-12-22 2011-06-30 Baxter International Inc. Vaccine to Influenza A Virus
US20130115234A1 (en) * 2010-03-26 2013-05-09 Emergent Product Development Gaithersburg,Inc. Ectodomains of Influenza Matrix 2 Protein, Expression System, and Uses Thereof
NZ603620A (en) 2010-07-20 2015-01-30 Bavarian Nordic As Method for harvesting expression products
EP2618840A2 (en) * 2010-09-23 2013-07-31 Baxter International Inc. Recombinant viral vectors and methods for inducing an immune response to yellow fever virus
US9173933B2 (en) 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
ES2733211T3 (es) 2011-04-15 2019-11-28 Genelux Corp Cepas clonales de virus vaccinia atenuados y métodos de uso de las mismas
WO2013083254A1 (en) 2011-12-09 2013-06-13 Bavarian Nordic A/S Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
US20150150963A1 (en) 2012-06-05 2015-06-04 The Australian National University Vaccination with interleukin-4 antagonists
CA2879915C (en) 2012-08-01 2022-07-05 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine
WO2014043535A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions for the treatment of cancer
WO2014055960A1 (en) 2012-10-05 2014-04-10 Genelux Corporation Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes
JP2016502507A (ja) 2012-10-19 2016-01-28 バヴァリアン・ノルディック・インコーポレイテッド 癌治療のための組成物および方法
DE102013004595A1 (de) 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
WO2014138824A1 (en) * 2013-03-15 2014-09-18 Sementis Limited Immune modulation
WO2014139587A1 (en) * 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
KR101623498B1 (ko) 2014-10-16 2016-05-24 대한민국 약독화 백시니아 바이러스주 kvac１０３
KR101645642B1 (ko) 2014-10-16 2016-08-11 대한민국 Kvac１０３ 유래의 재조합 백시니아 바이러스
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
KR20160140075A (ko) * 2015-05-29 2016-12-07 코오롱생명과학 주식회사 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터
AU2016278806A1 (en) 2015-06-15 2017-12-14 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
CN106591361A (zh) * 2015-10-20 2017-04-26 钱文斌 一种重组痘溶瘤病毒及其构建方法和应用
CA3011014A1 (en) * 2016-01-08 2017-07-13 Harriet Robinson Compositions and methods for generating an immune response to a tumor associated antigen
HUE059343T2 (hu) 2016-01-29 2022-11-28 Bavarian Nordic As Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
BR112018015696A2 (pt) * 2016-02-03 2018-12-26 Geovax Inc composições e métodos para gerar uma resposta imune para um flavivírus
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS
EP3452087A1 (en) 2016-05-02 2019-03-13 Janssen Vaccines & Prevention B.V. Therapeutic hpv vaccine combinations
MX2019001919A (es) * 2016-08-19 2019-09-04 Sementis Ltd Vacunas virales.
US20200024610A1 (en) * 2016-09-30 2020-01-23 Monsanto Technology Llc Method for selecting target sites for site-specific genome modification in plants
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
CN110958887B (zh) * 2017-06-15 2023-10-31 扬森疫苗与预防公司 编码hiv抗原的痘病毒载体及其使用方法
US11311612B2 (en) 2017-09-19 2022-04-26 Geovax, Inc. Compositions and methods for generating an immune response to treat or prevent malaria
EP3790579A4 (en) * 2018-05-11 2022-06-15 City of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
EP3790578A4 (en) 2018-05-11 2022-04-06 City of Hope Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
CN111979204B (zh) * 2019-05-24 2023-10-13 杭州功楚生物科技有限公司 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途
CA3161633A1 (en) 2019-11-14 2021-05-20 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP3842065A1 (en) * 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
US20210299245A1 (en) * 2020-03-31 2021-09-30 Sementis Limited Attenuated poxvirus vector based vaccine for protection against covid-19
CN117177763A (zh) 2021-02-02 2023-12-05 吉奥瓦科斯公司 用于增强疫苗接种期间的t细胞启动的病毒构建体
WO2024011250A1 (en) 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof
FR3160186A1 (fr) 2024-03-13 2025-09-19 Odimma Therapeutics Vecteur non-viral pour transcription augmentee

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
JPH0795956B2 (ja) * 1986-09-22 1995-10-18 京都大学長 ポックスウイルス由来発現制御領域
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5651972A (en) 1989-04-21 1997-07-29 University Of Florida Research Foundation, Inc. Use of recombinant swine poxvirus as a live vaccine vector
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US6893845B1 (en) * 1990-09-28 2005-05-17 Applied Molecular Evolution, Inc. Surface expression libraries of heteromeric receptors
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
BE1004877A3 (fr) * 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
FR2679249B1 (fr) * 1991-07-15 1993-11-26 Centre Nal Recherc Scientifique Souches de levure avec integration stable de genes heterologues.
JPH06509235A (ja) 1991-07-26 1994-10-20 ヴァイロジェネティクス　コーポレイション 伝染性ファブリキウス嚢病ウイルス組換えポックスウイルスワクチン
DE69133333T2 (de) * 1991-08-26 2004-07-29 Baxter Healthcare S.A. Ein intaktes FPV-tk-Gen enthaltender rekombinanter Virus der Vogelpocken
EP0561034B1 (en) * 1991-08-26 1999-06-09 IMMUNO Aktiengesellschaft Direct molecular cloning of a modified chordopox virus genome
US5676950A (en) 1994-10-28 1997-10-14 University Of Florida Enterically administered recombinant poxvirus vaccines
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
EP0753581A1 (en) * 1995-07-10 1997-01-15 Immuno Ag Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
AU4556597A (en) * 1996-09-24 1998-04-17 Bavarian Nordic Research Institute A/S Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
AUPP380598A0 (en) * 1998-05-29 1998-06-25 Commonwealth Scientific And Industrial Research Organisation Genetically manipulated entomopoxvirus
US6252871B1 (en) 1998-07-01 2001-06-26 Powerwave Technologies, Inc. Switchable combiner/splitter
US20040265324A1 (en) * 1999-03-23 2004-12-30 Cardosa Mary Jane Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines
WO2000073476A1 (en) * 1999-05-28 2000-12-07 Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh Vector for integration of heterologous sequences into poxviral genomes
BR0109158A (pt) * 2000-03-14 2003-04-22 Anton Mayr Cepa alterada do vìrus de varìola bovina de ankara (mva)
CA2341356C (en) * 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
CN1250731C (zh) * 2000-08-29 2006-04-12 惠氏控股公司 正链rna病毒复制子颗粒的包装
NZ524661A (en) * 2000-11-23 2005-03-24 Bavarian Nordic As Modified vaccinia ankara virus variant
EP1407033B1 (en) * 2002-05-16 2006-01-11 Bavarian Nordic A/S Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
KR20050083839A (ko) * 2002-11-25 2005-08-26 버베리안 노딕 에이/에스 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스

Also Published As

Publication number Publication date
AU2003236646A1 (en) 2003-12-02
KR101041691B1 (ko) 2011-06-14
NZ536501A (en) 2006-08-31
MXPA04011194A (es) 2005-02-14
EA200401507A1 (ru) 2005-06-30
ES2256776T3 (es) 2006-07-16
US20100303856A1 (en) 2010-12-02
HK1076836A1 (zh) 2006-01-27
US20100173388A1 (en) 2010-07-08
IL164172A0 (en) 2005-12-18
PL372093A1 (en) 2005-07-11
US8414900B2 (en) 2013-04-09
EA012160B1 (ru) 2009-08-28
NO334273B1 (no) 2014-01-27
US7964374B2 (en) 2011-06-21
WO2003097845A1 (en) 2003-11-27
JP2010259446A (ja) 2010-11-18
EP1506301B1 (en) 2014-04-30
AU2003242540A1 (en) 2003-12-02
NO336489B1 (no) 2015-09-07
PL218318B1 (pl) 2014-11-28
PT1407033E (pt) 2006-05-31
CA2481799A1 (en) 2003-11-27
US20110053260A1 (en) 2011-03-03
US20120082696A1 (en) 2012-04-05
PL372088A1 (en) 2005-07-11
BRPI0311178B1 (pt) 2020-11-17
AU2003236646B2 (en) 2009-01-15
IL164177A0 (en) 2005-12-18
US7550147B2 (en) 2009-06-23
US9109233B2 (en) 2015-08-18
IL193088A0 (en) 2009-02-11
US20120135501A1 (en) 2012-05-31
DE60303218D1 (de) 2006-04-06
JP5777199B2 (ja) 2015-09-09
NO20044940L (no) 2004-11-12
KR20040108798A (ko) 2004-12-24
DK1407033T3 (da) 2006-05-22
SI1407033T1 (sl) 2006-06-30
PL216760B1 (pl) 2014-05-30
KR101005630B1 (ko) 2011-01-05
US20060165727A1 (en) 2006-07-27
KR20120002627A (ko) 2012-01-06
US7338662B2 (en) 2008-03-04
IL193088A (en) 2015-02-26
MXPA04010713A (es) 2005-03-07
NO20045480L (no) 2004-12-16
BRPI0311178B8 (pt) 2021-05-25
JP2005525822A (ja) 2005-09-02
AU2009200380A1 (en) 2009-02-19
EA020230B1 (ru) 2014-09-30
CN101831411A (zh) 2010-09-15
US20110250693A1 (en) 2011-10-13
BR0310051A (pt) 2005-02-15
ATE315660T1 (de) 2006-02-15
EP1407033B1 (en) 2006-01-11
US20120178157A1 (en) 2012-07-12
US20090311746A1 (en) 2009-12-17
JP2011004755A (ja) 2011-01-13
DK1506301T3 (da) 2014-07-21
US8309326B2 (en) 2012-11-13
KR20040108809A (ko) 2004-12-24
JP2005525823A (ja) 2005-09-02
HK1076642A1 (en) 2006-01-20
EA007811B1 (ru) 2007-02-27
BR0311178A (pt) 2005-03-29
NZ536502A (en) 2005-10-28
US8288125B2 (en) 2012-10-16
KR101138067B1 (ko) 2012-04-24
CA2481799C (en) 2014-01-28
AU2009200380B2 (en) 2009-10-01
EA200900180A1 (ru) 2009-08-28
CA2481521A1 (en) 2003-11-27
US20050244428A1 (en) 2005-11-03
CN1653183A (zh) 2005-08-10
US20120039936A1 (en) 2012-02-16
CN1653183B (zh) 2012-07-25
EP2253709B1 (en) 2018-04-11
CN1653184A (zh) 2005-08-10
CN102199628A (zh) 2011-09-28
CN102703393A (zh) 2012-10-03
UA82479C2 (uk) 2008-04-25
US8034354B2 (en) 2011-10-11
US8435543B2 (en) 2013-05-07
CA2481521C (en) 2012-04-17
US8741308B2 (en) 2014-06-03
AU2009200380C1 (en) 2010-03-11
EP2253709A1 (en) 2010-11-24
EP1407033A1 (en) 2004-04-14
US20110244574A1 (en) 2011-10-06
KR20100110901A (ko) 2010-10-13
US20110053259A1 (en) 2011-03-03
JP4693092B2 (ja) 2011-06-01
AU2008255213A1 (en) 2009-01-08
WO2003097846A1 (en) 2003-11-27
EA200401506A1 (ru) 2005-04-28
EP1506301A1 (en) 2005-02-16
NO20111324A1 (no) 2011-09-29
AU2008255213B2 (en) 2011-10-06
US20130243813A1 (en) 2013-09-19
CN100494388C (zh) 2009-06-03
IL193087A (en) 2012-10-31
DE60303218T2 (de) 2006-09-14
CA2812019A1 (en) 2003-11-27
CN102719408A (zh) 2012-10-10
IL193087A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
JP4895505B2 (ja) 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
US8323661B2 (en) Method for generating a stable recombinant modified vaccinia virus ankara (MVA) comprising human immunodeficiency virus (HIV) genes inserted into one or more intergenic regions (IGRs)
KR20050083839A (ko) 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스
AU2007200016B2 (en) Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of modified vaccinia virus ankara
HK1076836B (en) Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090907

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20110106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110107

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110412

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111220

R150 Certificate of patent or registration of utility model

Ref document number: 4895505

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term